Actavis Inc (ACT) 217.45 $ACT
Is Teva Pharmaceuticals Stock Really Your Best Generic Drug Investment Option?
Brian Nichols, The Motley Fool - Motley Fool - Thu Jul 24, 7:54AM CDT
UBS made news over the weekend with its list of six stocks that could soar behind key catalysts not priced into each respective company. Within that list is Teva Pharmaceuticals , a company that UBS believes will benefit from continued patent...
Pharma, Biotech M&As Heat Up: Tax Inversion in Focus - Industry Outlook
Arpita Dutt - Zacks Investment Research - Thu Jul 24, 2:47AM CDT
Pharma, Biotech M&As Heat Up: Tax Inversion in Focus - Industry Outlook
Pharma, Biotech M&As Heat Up: Tax Inversion in Focus - Zacks Analyst Interviews
Arpita Dutt - Zacks Investment Research - Thu Jul 24, 2:47AM CDT
Pharma, Biotech M&As Heat Up: Tax Inversion in Focus - Zacks Analyst Interviews
World Market for Biosimilars (EPO, G-CSF, HGH, Insulin, Interferon alpha, mAbs, Others) 2013-2017
M2 - Wed Jul 23, 3:02AM CDT
Research and Markets (http://www.researchandmarkets.com/research/tpvpdw/the_world_market) has announced the addition of the "The World Market for Biosimilars, 4th Edition (EPO, G-CSF, HGH, Insulin, Interferon alpha, mAbs, Others)" report to their offering. This study, The World Market for Biosimilars, 4th Edition (EPO, G-CSF, HGH, Insulin, Interferon alpha, mAbs, Others), is designed to provide a comprehensive look at the various strategies being used by select worldwide generic companies in exploring the emerging area of biosimilars, the issues and trends that are shaping the marketplace, and the potential feasibility of providing biosimilars within the United States regulatory environment. Generic drugs continue to represent one of the greatest values in healthcare and are of great importance in the area of biopharmaceuticals as well because these products are among the most expensive treatments currently on the market. Generic drug manufacturers are poised for strong growth in the future because the patent protection for a host of major biopharmaceuticals will expire and new legislative reforms in the generic drug approval process may facilitate bringing products to market. While there are many issues to address, the outlook for biosimilar promotion is favorable in the next five years. As part of its coverage, the report provides the following: - Marketed Biologics with Expired Patents - Marketed Biologics with Active Patents - Cost Savings From Biosimilar Use - World Biosimilar Market Potential by Region 2010-2017 - Biosimilars Pipeline by Company and Product Type - Scientific Differences of Pharmaceuticals and Biopharmaceuticals - Market Share of Biosimilar Sales in Comparison to Brand Sales - World Biosimilar Market Potential by Biological Class 2010-2017 ( EPO, G-CSF, HGH, Insulin, Interferon Alpha, Monoclonal Antibodies, Other) Key Topics Covered: 1. Executive Summary 2. Introduction And Overview 3. Biosimilar Pharmaceuticals For Expired Biologic Patents 4. Biosimilar Pharmaceuticals For Future Expired Biologic Patents 5. Issues And Trends 6. Market Summary 7. Corporate Profiles - 3SBio, Inc - Actavis, Inc. - Apotex, Inc. - Beijing Four Rings Biopharmaceutical Co Ltd - Biocad - Biocon Ltd . - Bio Sidus S.A. - BioXpress Therapeutics S.A. - Boehringer Ingelheim Gmbh - Celltrion, Inc. - Dong-A Pharmaceutical - Dr. Reddy's Laboratories Limited - Epirus Biopharmaceuticals - Gedeon Richter - Harvest Moon Pharmaceuticals USA, - Hospira, Inc. - Kyowa Hakko Kirin Co., Ltd. - Merck & Company - Momenta Pharmaceuticals Inc - Phage Pharmaceuticals, Inc. - Ranbaxy Laboratories Limited - Reliance GeneMedix PLC - Reliance Life Sciences - Samsung Bioepis Co Ltd - Sandoz International GmbH - STADA Arzneimittel AG - TEVA Pharmaceutical Industries, Ltd. - Wockhardt Ltd. - Xiamen Amoytop Biotech Co Ltd. For more information visit http://www.researchandmarkets.com/research/tp...rld_market About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Medicines360 and Actavis files Levosert IUD's NDA for US FDA's substantive review
M2 - Tue Jul 22, 8:15AM CDT
Pharmaceutical company Medicines360 disclosed on Monday that the US Food and Drug Administration (FDA) has accepted for filing its New Drug Application (NDA) for Levosert in partnershp with Actavis (NYSE:ACT).
Medicines360 and Actavis Announce FDA Acceptance for Filing of NDA for Levosert(TM) IUD
PR Newswire - Mon Jul 21, 3:30PM CDT
Medicines360, a non-profit women's health pharmaceutical company, and Actavis plc (NYSE: ACT), a leading global specialty pharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing Medicines360's New Drug Application (NDA) for Levosert(TM) (levonorgestrel), a hormonal intrauterine contraceptive (IUC) for use by women to prevent pregnancy.
Synergy Pharmaceuticals Progresses with Mid-Stage Candidate - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jul 18, 5:15PM CDT
Synergy Pharmaceuticals (SGYP) completed patient enrollment for its phase II study on SP-333.
Enable Partners, Other Leaders Facing Market Pressure
at Investor's Business Daily - Fri Jul 18, 5:10PM CDT
When the market is under pressure, stocks often face a tougher time following through on breakouts, and this time around is no exception. Actavis (ACT), Concho Resources (CXO) and Enable Midstream Partners (ENBL) are among leading Spotlight stocks...
Glance: Biggest corporate deals so far this year
By The Associated Press - AP - Fri Jul 18, 10:58AM CDT
Abbvie Inc.'s deal to combine with Shire PLC would be the largest made so far this year, excluding assumed debt. Here are the top five:
Mylan (MYL) Joins the Tax-Inversion Wave - Analyst Blog
Swarup Gupta - Zacks Investment Research - Wed Jul 16, 12:03PM CDT
More M&A activity involving tax-inversion can be expected in the days ahead.
Facebook, Apple Suppliers Lead 5 Big-Cap All-Stars
at Investor's Business Daily - Wed Jul 16, 8:16AM CDT
Looking for Wall Street's stock all-stars? IBD's Screen of the Day is Big Cap Leaders, which includes the top-performing large-cap stocks with strong fundamentals and technicals. This article focuses on the screen's five companies including social...
Mylan to Buy Abbott Generic Drug Unit - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Jul 15, 4:10PM CDT
Mylan (MYL) will buy Abbott's (ABT) non-U.S. developed markets specialty and branded generics business.
Actavis Fuels Growth With Acquisitions, New Generics
at Investor's Business Daily - Mon Jul 14, 4:30PM CDT
Actavis (ACT) has kept busy on the merger and acquisition trail the past couple of years. Since closing its acquisition of Forest Laboratories on July 2, when new CEO (and former Forest chief) Brenton Saunders took the helm, Actavis has completed a...
Drug Application Submission, Merger Agreement, Launch of Newly Approved Drug, and Acquisition - Analyst Notes on Actavis, Salix, Mylan, Zoetis and Hospira
PR Newswire - Mon Jul 14, 4:10AM CDT
Today, Analysts Review released its analysts' notes regarding Actavis plc (NYSE: ACT), Salix Pharmaceuticals, Ltd. (NASDAQ: SLXP), Mylan Inc. (NASDAQ: MYL), Zoetis Inc. (NYSE: ZTS) and Hospira, Inc. (NYSE: HSP). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/4724-100free.
Actavis Confirms Generic Diclegis® Patent Challenge
PR Newswire - Fri Jul 11, 3:25PM CDT
Actavis plc (NYSE: ACT) today confirmed that it has filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market Doxylamine Succinate and Pyridoxine Hydrochloride Delayed-release tablets, 10 mg/10 mg. Actavis' ANDA product is a generic version of Duchesnay Inc.'s Diclegis®, which is indicated for the treatment of nausea and vomiting of pregnancy in women who do not respond to conservative management.
Synergy Pharmaceuticals' Plecanatide to Move into Phase III - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jul 09, 4:10PM CDT
Synergy Pharmaceuticals (SGYP) intends to start a pivotal phase III study on its lead pipeline candidate, plecanatide.
ACTAVIS
at Investor's Business Daily - Tue Jul 08, 5:47PM CDT
ACTAVIS (ACT), a drugmaker, filed for FDA to OK marketing dalfampridine extended release tabs, a generic of multiple sclerosis drug Ampyra.
Actavis Confirms Generic Ampyra® Patent Challenge
PR Newswire - Tue Jul 08, 3:05PM CDT
Actavis plc (NYSE: ACT) today confirmed that it has filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market Dalfampridine Extended-release Tablets, 10 mg. Actavis' ANDA product is a generic version of Acorda Therapeutics' Ampyra®, which is indicated as a treatment to improve walking in patients with multiple sclerosis.
Stocks Ease Off Lows; King Digital Turns Tail
at Investor's Business Daily - Tue Jul 08, 12:28PM CDT
Stocks were still firmly lower Tuesday afternoon, but they have come slightly off their worst levels. The Nasdaq trimmed a 1.8% loss to 1.4%. Energy, Internet and solar stocks continued to be the worst-performing groups in the stock market today....
Is Teva Pharmaceuticals Stock Really Your Best Generic Drug Investment Option?
Brian Nichols, The Motley Fool - Motley Fool - Thu Jul 24, 7:54AM CDT
UBS made news over the weekend with its list of six stocks that could soar behind key catalysts not priced into each respective company. Within that list is Teva Pharmaceuticals , a company that UBS believes will benefit from continued patent...
Pharma, Biotech M&As Heat Up: Tax Inversion in Focus - Industry Outlook
Arpita Dutt - Zacks Investment Research - Thu Jul 24, 2:47AM CDT
Pharma, Biotech M&As Heat Up: Tax Inversion in Focus - Industry Outlook
Pharma, Biotech M&As Heat Up: Tax Inversion in Focus - Zacks Analyst Interviews
Arpita Dutt - Zacks Investment Research - Thu Jul 24, 2:47AM CDT
Pharma, Biotech M&As Heat Up: Tax Inversion in Focus - Zacks Analyst Interviews
World Market for Biosimilars (EPO, G-CSF, HGH, Insulin, Interferon alpha, mAbs, Others) 2013-2017
M2 - Wed Jul 23, 3:02AM CDT
Research and Markets (http://www.researchandmarkets.com/research/tpvpdw/the_world_market) has announced the addition of the "The World Market for Biosimilars, 4th Edition (EPO, G-CSF, HGH, Insulin, Interferon alpha, mAbs, Others)" report to their offering. This study, The World Market for Biosimilars, 4th Edition (EPO, G-CSF, HGH, Insulin, Interferon alpha, mAbs, Others), is designed to provide a comprehensive look at the various strategies being used by select worldwide generic companies in exploring the emerging area of biosimilars, the issues and trends that are shaping the marketplace, and the potential feasibility of providing biosimilars within the United States regulatory environment. Generic drugs continue to represent one of the greatest values in healthcare and are of great importance in the area of biopharmaceuticals as well because these products are among the most expensive treatments currently on the market. Generic drug manufacturers are poised for strong growth in the future because the patent protection for a host of major biopharmaceuticals will expire and new legislative reforms in the generic drug approval process may facilitate bringing products to market. While there are many issues to address, the outlook for biosimilar promotion is favorable in the next five years. As part of its coverage, the report provides the following: - Marketed Biologics with Expired Patents - Marketed Biologics with Active Patents - Cost Savings From Biosimilar Use - World Biosimilar Market Potential by Region 2010-2017 - Biosimilars Pipeline by Company and Product Type - Scientific Differences of Pharmaceuticals and Biopharmaceuticals - Market Share of Biosimilar Sales in Comparison to Brand Sales - World Biosimilar Market Potential by Biological Class 2010-2017 ( EPO, G-CSF, HGH, Insulin, Interferon Alpha, Monoclonal Antibodies, Other) Key Topics Covered: 1. Executive Summary 2. Introduction And Overview 3. Biosimilar Pharmaceuticals For Expired Biologic Patents 4. Biosimilar Pharmaceuticals For Future Expired Biologic Patents 5. Issues And Trends 6. Market Summary 7. Corporate Profiles - 3SBio, Inc - Actavis, Inc. - Apotex, Inc. - Beijing Four Rings Biopharmaceutical Co Ltd - Biocad - Biocon Ltd . - Bio Sidus S.A. - BioXpress Therapeutics S.A. - Boehringer Ingelheim Gmbh - Celltrion, Inc. - Dong-A Pharmaceutical - Dr. Reddy's Laboratories Limited - Epirus Biopharmaceuticals - Gedeon Richter - Harvest Moon Pharmaceuticals USA, - Hospira, Inc. - Kyowa Hakko Kirin Co., Ltd. - Merck & Company - Momenta Pharmaceuticals Inc - Phage Pharmaceuticals, Inc. - Ranbaxy Laboratories Limited - Reliance GeneMedix PLC - Reliance Life Sciences - Samsung Bioepis Co Ltd - Sandoz International GmbH - STADA Arzneimittel AG - TEVA Pharmaceutical Industries, Ltd. - Wockhardt Ltd. - Xiamen Amoytop Biotech Co Ltd. For more information visit http://www.researchandmarkets.com/research/tp...rld_market About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Medicines360 and Actavis files Levosert IUD's NDA for US FDA's substantive review
M2 - Tue Jul 22, 8:15AM CDT
Pharmaceutical company Medicines360 disclosed on Monday that the US Food and Drug Administration (FDA) has accepted for filing its New Drug Application (NDA) for Levosert in partnershp with Actavis (NYSE:ACT).
Medicines360 and Actavis Announce FDA Acceptance for Filing of NDA for Levosert(TM) IUD
PR Newswire - Mon Jul 21, 3:30PM CDT
Medicines360, a non-profit women's health pharmaceutical company, and Actavis plc (NYSE: ACT), a leading global specialty pharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing Medicines360's New Drug Application (NDA) for Levosert(TM) (levonorgestrel), a hormonal intrauterine contraceptive (IUC) for use by women to prevent pregnancy.
Synergy Pharmaceuticals Progresses with Mid-Stage Candidate - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jul 18, 5:15PM CDT
Synergy Pharmaceuticals (SGYP) completed patient enrollment for its phase II study on SP-333.
Enable Partners, Other Leaders Facing Market Pressure
at Investor's Business Daily - Fri Jul 18, 5:10PM CDT
When the market is under pressure, stocks often face a tougher time following through on breakouts, and this time around is no exception. Actavis (ACT), Concho Resources (CXO) and Enable Midstream Partners (ENBL) are among leading Spotlight stocks...
Glance: Biggest corporate deals so far this year
By The Associated Press - AP - Fri Jul 18, 10:58AM CDT
Abbvie Inc.'s deal to combine with Shire PLC would be the largest made so far this year, excluding assumed debt. Here are the top five:
Mylan (MYL) Joins the Tax-Inversion Wave - Analyst Blog
Swarup Gupta - Zacks Investment Research - Wed Jul 16, 12:03PM CDT
More M&A activity involving tax-inversion can be expected in the days ahead.
Facebook, Apple Suppliers Lead 5 Big-Cap All-Stars
at Investor's Business Daily - Wed Jul 16, 8:16AM CDT
Looking for Wall Street's stock all-stars? IBD's Screen of the Day is Big Cap Leaders, which includes the top-performing large-cap stocks with strong fundamentals and technicals. This article focuses on the screen's five companies including social...
Mylan to Buy Abbott Generic Drug Unit - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Jul 15, 4:10PM CDT
Mylan (MYL) will buy Abbott's (ABT) non-U.S. developed markets specialty and branded generics business.
Actavis Fuels Growth With Acquisitions, New Generics
at Investor's Business Daily - Mon Jul 14, 4:30PM CDT
Actavis (ACT) has kept busy on the merger and acquisition trail the past couple of years. Since closing its acquisition of Forest Laboratories on July 2, when new CEO (and former Forest chief) Brenton Saunders took the helm, Actavis has completed a...
Drug Application Submission, Merger Agreement, Launch of Newly Approved Drug, and Acquisition - Analyst Notes on Actavis, Salix, Mylan, Zoetis and Hospira
PR Newswire - Mon Jul 14, 4:10AM CDT
Today, Analysts Review released its analysts' notes regarding Actavis plc (NYSE: ACT), Salix Pharmaceuticals, Ltd. (NASDAQ: SLXP), Mylan Inc. (NASDAQ: MYL), Zoetis Inc. (NYSE: ZTS) and Hospira, Inc. (NYSE: HSP). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/4724-100free.
Actavis Confirms Generic Diclegis® Patent Challenge
PR Newswire - Fri Jul 11, 3:25PM CDT
Actavis plc (NYSE: ACT) today confirmed that it has filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market Doxylamine Succinate and Pyridoxine Hydrochloride Delayed-release tablets, 10 mg/10 mg. Actavis' ANDA product is a generic version of Duchesnay Inc.'s Diclegis®, which is indicated for the treatment of nausea and vomiting of pregnancy in women who do not respond to conservative management.
Synergy Pharmaceuticals' Plecanatide to Move into Phase III - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jul 09, 4:10PM CDT
Synergy Pharmaceuticals (SGYP) intends to start a pivotal phase III study on its lead pipeline candidate, plecanatide.
ACTAVIS
at Investor's Business Daily - Tue Jul 08, 5:47PM CDT
ACTAVIS (ACT), a drugmaker, filed for FDA to OK marketing dalfampridine extended release tabs, a generic of multiple sclerosis drug Ampyra.
Actavis Confirms Generic Ampyra® Patent Challenge
PR Newswire - Tue Jul 08, 3:05PM CDT
Actavis plc (NYSE: ACT) today confirmed that it has filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market Dalfampridine Extended-release Tablets, 10 mg. Actavis' ANDA product is a generic version of Acorda Therapeutics' Ampyra®, which is indicated as a treatment to improve walking in patients with multiple sclerosis.
Stocks Ease Off Lows; King Digital Turns Tail
at Investor's Business Daily - Tue Jul 08, 12:28PM CDT
Stocks were still firmly lower Tuesday afternoon, but they have come slightly off their worst levels. The Nasdaq trimmed a 1.8% loss to 1.4%. Energy, Internet and solar stocks continued to be the worst-performing groups in the stock market today....
